168143-71-3

Upstream product

• 71095-42-6 5-chloro-3-methyl-1H-indole 
• 98-09-9 benzenesulfonyl chloride 
• 16382-20-0 5-chloro-3-methyl-1H-indole-2-carboxylic acid ethyl ester 
• 106-47-8 4-chloro-aniline 
• 16381-47-8 5-chloro-3-methyl-1H-indole-2-carboxylic acid 

Downstream Products

• 1394430-65-9 5-chloro-N-(4-methoxybenzyl)-3-methyl-1H-indole-2-sulfonamide 
• 1394430-60-4 5-chloro-3-methyl-1-(phenylsulfonyl)-1H-indole-2-sulfonylchloride 
• 1394430-64-8 5-chloro-N-(4-methoxybenzyl)-3-methyl-1-(phenylsulfonyl)-1H-indole-2-sulfonamide 
• 1394430-59-1 lithium 5-chloro-3-methyl-1-(phenylsulfonyl)-1H-indole-2-sulfinate 

Relevant academic research and scientific papers

Regiospecific Bromination of 3-Methylindoles with NBS and Its Application to the Concise Synthesis of Optically Active Unusual Tryptophans Present in Marine Cyclic Peptides

A regiospecific bromination of substituted 3-methylindoles at either the C(3) alkyl moiety or the C(2) position was achieved via a free radical bromination or electrophilic process, respectively. The regiospecificity of the bromination could be controlled by variation of both the substituent and the N(1) protecting group on the indole ring. In addition, enantiospecific syntheses of 5-methoxytryptophan (20) and 5-hydroxy-6-chlorotryptophan (21c) as well as concise syntheses of optically active 2-bromotryptophan ethyl esters 26a,b or their substituted derivatives in three steps from bifunctional dibromoindoles were achieved via the above regiospecific process.

N- (ARYLALKYL) - 1H- INDOLE- 2 - SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain /V-(arylalkyl)-1 H-indole- 2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein.